Posted: October 25, 2019
FACULTY OF MEDICINE & DENTISTRY, DEPARTMENT OF MEDICAL MICROBIOLOGY AND IMMUNOLOGY
Team: Michael Houghton, D. Lorne Tyrrell, Tim Lankisch (DE), Tobias Weismueller (DE), Michael Manns (DE)
Patent 9,952,226: Methods and compositions for diagnosis of inflammatory liver disease
The diagnosis of primary sclerosing cholangitis (PSC) is based on a set of complicated, invasive and/or expensive tools such as endoscopic retrograde holangiopancreatography (ERCP), magnetic resonance-CP (MRCP) and/or liver biopsy. The diagnosis is usually made at late stages of the disease with extensive scarring.
Furthermore, PSC is the only autoimmune liver disease with no treatment. Landi and his team discovered and described analytes in the blood of PSC patients that could serve as easier, less expensive and safer methods to diagnose the disease. As an important component of the described diagnostic algorithms in a parent patent, Eotaxin-1 (E1) reported to be highly involved in pathogenesis of liver fibrosis in PSC. This divisional patent specifically claims the use of an antibody that binds E1 for the treatment of PSC.
The TEC Edmonton Innovation Awards celebrate the success of University of Alberta researchers. In 2019, awards were presented to ten University of Alberta spin-off companies and nine research teams that received a US patent and have an industry partner.